Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

BioPharm Vertical Expands With Two Research Pilots Of DNA Therapeutics

By Applied DNA Sciences, Inc. | December 5, 2017

Applied DNA Sciences, Inc. has begun initial Research and Development pilots for the manufacture of DNA for use in DNA-based therapeutics for two companies. Several other companies have requested proposals for additional DNA-based therapeutics.

In one project, the company is engaged in evaluation of a DNA therapeutic with a U.S.-based customer and in the second, the company is conducting an evaluation of two animal vaccines with Evvivax srl, an Italian biotech company focused on healthcare for companion animals. These pilots will be developed using the company’s proprietary and patented large-scale PCR (polymerase chain reaction) DNA production processes and devices.

“PCR-production of DNA offers advantages over ‘plasmid produced’ DNA,” Dr. James Hayward, president and CEO of Applied DNA, said. “The goal of this pilot is to quantify those advantages for use in our animal vaccines.”

The new pilots complement current agreements to supply PCR-produced DNA to suppliers of diagnostics, according to Applied DNA. The company’s current customers develop the diagnostic tests, while Applied DNA acts as the long-term supplier of their customized DNA.

It is a natural extension to the company’s roadmap of DNA-tagging commercial pharmaceutics to secure supply chains of approved drugs, the company continued in a statement. The DNA tags are short, have no biological function by design, and are present as traceable “excipients,” which aid in the manufacture of finished drugs, but are not the Active Pharmaceutic Ingredients (APIs). The company’s portfolio now will include (longer) functional DNA therapeutics.

DNA vaccines have until now, been based primarily upon “plasmid” delivery. Plasmids are small, circular, double-stranded molecules of DNA found in bacteria and yeast. These molecules have traditionally been the tools used to manufacture DNA.

However, a plasmid-based technology for gene therapy suffers from a number of drawbacks that include: a) the active DNA only represents about 30-50 percent of the plasmid, b) the remaining 50-70 percent of the plasmid contains multiple genetic components unrelated to the DNA vaccine that may have unintended consequences in humans, c) the plasmid-containing bacteria must be grown in very large vessels, over many days, to yield DNA supplies adequate for vaccines, d) the bacteria used to produce the plasmids contain toxins and pyrogens, that can cause illness and fevers if present in the DNA preparation that is given to a patient.

PCR-produced DNA is very pure, especially compared to plasmids. Bacteria are not used during manufacturing. The reaction starting materials are limited to the nucleotides (adenine, thymine, guanine and cytosine) contained within the target sequence, an enzyme called polymerase, the template for the target DNA and primers.

Almost all the starting materials are consumed during the reaction. Any residual reactants are easily removed during purification of the target DNA, due especially to the latter’s far greater size. Most importantly, the PCR-produced DNA contains only the DNA elements required for DNA therapeutic function and is free of any of the extraneous genetic elements intrinsic to a plasmid-based carrier.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE